Barbara Ruggiero
Overview
Explore the profile of Barbara Ruggiero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1059
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trepiccione F, Sambri I, Ruggiero B, Emma F, Ballabio A, Florio G, et al.
Kidney Blood Press Res
. 2024 Jun;
49(1):637-645.
PMID: 38901414
Background: A hereditary condition primarily affecting the kidneys and heart has newly been identified: the RRAGD-associated autosomal dominant kidney hypomagnesemia with cardiomyopathy (ADKH-RRAGD). This disorder is characterized by renal loss...
2.
Ruggenenti P, Reinhard L, Ruggiero B, Perna A, Perico L, Peracchi T, et al.
Am J Kidney Dis
. 2023 Dec;
83(5):588-600.e1.
PMID: 38151224
Rationale & Objective: Proteinuria and anti-phospholipase A receptor 1 (anti-PLAR1) antibody titers are associated with primary membranous nephropathy (MN) outcomes. We evaluated the association of antibodies against the cysteine-rich (CysR)...
3.
Casiraghi F, Todeschini M, Podesta M, Mister M, Ruggiero B, Trillini M, et al.
Int J Mol Sci
. 2023 May;
24(9).
PMID: 37175393
Immune dysregulation plays a key role in the pathogenesis of steroid-dependent/frequently relapsing nephrotic syndrome (SDNS/FRNS). However, in contrast with evidence from the pediatric series, no major B- or T-cell alterations...
4.
Perna A, Ruggiero B, Podesta M, Perico L, Orisio S, Debiec H, et al.
Front Pharmacol
. 2022 Sep;
13:958136.
PMID: 36120314
Rituximab is one of the first-line therapies for patients with membranous nephropathy (MN) at high risk of progression towards kidney failure. We investigated whether the response to Rituximab was affected...
5.
Caroli A, Remuzzi A, Ruggiero B, Carrara C, Rizzo P, Brambilla P, et al.
Kidney Med
. 2020 Dec;
2(6):804-809.
PMID: 33319205
In recent years, kidney functional magnetic resonance imaging (MRI) has seen great advances, with several cross-sectional studies demonstrating correlations between MRI biomarkers and glomerular filtration rate. However, the potential of...
6.
Gargiulo A, Massella L, Ruggiero B, Rava L, Ciofi Degli Atti M, Materassi M, et al.
Kidney Int
. 2020 Nov;
99(2):475-483.
PMID: 33152448
Corticosteroid-related toxicity in children with steroid-sensitive nephrotic syndrome is primarily related to the cumulative dose of prednisone. To optimize treatment of relapses, we conducted the PROPINE study, a multicentric, open-label,...
7.
Colucci M, Ruggiero B, Gianviti A, Rosado M, Carsetti R, Bracaglia C, et al.
Pediatr Nephrol
. 2020 Oct;
36(4):909-916.
PMID: 33025206
Background: Children with systemic lupus erythematosus (SLE) frequently have kidney involvement. Lupus nephritis sometimes presents alone, without systemic SLE features, representing the so-called full-house nephropathy (FHN). Distinguishing patients with SLE...
8.
Oni L, Gritzfeld J, Jones C, Sinha M, Wallace D, Stack M, et al.
Rheumatology (Oxford)
. 2020 Apr;
60(5):e179-e180.
PMID: 32337557
No abstract available.
9.
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness
Podesta M, Ruggiero B, Remuzzi G, Ruggenenti P
BMJ Case Rep
. 2020 Jan;
13(1).
PMID: 31980477
Rituximab (375 mg/m) achieved remission of the first episode and six relapses of nephrotic syndrome (NS) in a young male patient with podocyte phospholipase A receptor (PLAR)-related membranous nephropathy (MN)...
10.
Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, et al.
Am J Kidney Dis
. 2019 Apr;
74(3):338-350.
PMID: 31027883
Rationale & Objective: Hyperphosphatemia is associated with increased risk for chronic kidney disease (CKD) progression and reduced antiproteinuric effects of renin-angiotensin system (RAS) blockers. We investigated whether the phosphate binder...